Cutaneous Ulcers Associated with Hydroxyurea Therapy in Myeloproliferative Disorders

References

• Dressler WFC, Stein R. Uber den hydroxylhamstoff. Justus Liebig's Ann Chem Pharm 1869; 150: 242–252
   Google Scholar
• Rosenthal F, Wislicki L, Kollek L. Uber die beziehun-gen von schwersten blutgiften zu abbauprodukten des eiweisses : Ein beitrag zum entstehungsmechanismus der perniziosen anamie. Klin Wochenschr 1928; 7: 972–977
   Google Scholar
• Stock CC, Clarke DA, Philips FS, Barclay RK. Sarcoma 180 screening data. Cancer Res 1960; 20: 193–381
   PubMed Web of Science ®Google Scholar
• Steams B, Losee KA, Bernstein J, Hydroxyurea. A new type of potential antitumor agent. J Med Chem 1963; 6: 201
   PubMed Web of Science ®Google Scholar
• Donehower RC. An overview of the clinical experience with hydroxyurea. Semin Oncol 1992; 19%(3 suppl. 9)11
   PubMed Web of Science ®Google Scholar
• Lon F, Gallo RC. Hydroxyurea and AIDS : An old drug finds a new application ?. Retroviruses 1995; 11(10)1149–1151
   PubMed Web of Science ®Google Scholar
• Lori F, Malykh A, Cara A, Sun D, Weinstein JN, Lisziewicz J, Gallo RC. Hydroxyurea as an inhibitor of Human Immunodeficiency Virus - type 1 replication. Science 1994; 266(5186)801–805
   PubMed Web of Science ®Google Scholar
• Montaner JS, Zala C, Conway B, Raboud J, Patenaude P, Rae S, Oshaughnessy MV, Schechter MT. A pilot study of hydroxyurea among patients with advanced Human Immunodefeciency Vierus (HIV) disease receiving chronic didanosine therapy. Canadian HN trials network prtocol 080. J Infect Diseases 1997; 175(4)801–806
   PubMed Web of Science ®Google Scholar
• Biron F, Lucht F, Peyramond D, Fresard A, Vallet T, Nugier F, Grange J, Malley S, Hamedi-Sangsari F, Vila J. Pilot clinical trial of the combination of hydroxyurea and didanosine in HIV-1 infected individuals. Antiviral Research 1996; 29(1)111–113
   PubMed Web of Science ®Google Scholar
• Kennedy BJ. Hydroxyurea therapy in chronic myelogenous leukemia. Cancer 1972; 29: 1052–1056
   PubMed Web of Science ®Google Scholar
• Bolin RW, Robinson WA, Sutherland J, Hamman RF. Busulfan versus hydroxyurea in long term therapy of chronic myelogenous leukemia. Cancer 1982; 50: 1683–1686
   PubMed Web of Science ®Google Scholar
• Hehlmann R, Heimpel H, Hasford J, Kolb HJ, Pralle H, Hoss-Feld DK, Queisser W, Loffler H, Hochhaus A, Heinze B. Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. Blood 1994; 84: 4064–4077
   PubMed Web of Science ®Google Scholar
• Donovan PB, Kaplan ME, Goldberg JD, Tatarsky I, Najean Y, Silberstein EB, Knospe WH, Laszlo J, Mack K, Berk PD. Treatment of polycythemia Vera with hydroxyurea. Am J Hematol 1984; 17: 329–334
   PubMed Web of Science ®Google Scholar
• Cortelazzo S, Finazzi G, Ruggeri M, Vestri O, Galli M, Rodeghiero E Barbui T. Hydroxyurea for patients with essential thrombocythernia and a high risk of thrornbosis. New Eng J Med 1995; 332: 1132–1136
   PubMed Web of Science ®Google Scholar
• Silver FS, Espinoza LR, Hartmann RC. Acral erythema and hydroxyurea. Annals Int Med 1983; 98: 675, (Letter]
   PubMed Web of Science ®Google Scholar
• Bonner A, Hood AF. Cutaneous complications of che-motherapeutic agents. J Am Acad Derm 1983; 9: 645–663
   PubMed Web of Science ®Google Scholar
• Bums DA, Sarkany I. Effects of hydroxyurea therapy on normal skin. A case report. Clin Exp Dermatol. 1980; 5: 447–449
   PubMed Web of Science ®Google Scholar
• Dunagin WG. Clinical toxicity of chemotherapeutic agents : dermatologic toxicity. Semin Oncol. 1982; 9: 14–22
   PubMed Web of Science ®Google Scholar
• Kennedy BJ, Smith LR. Skin changes secondary to hydroxyurea therapy. Arch Dennatol 1975; 111: 183–187
   PubMed Web of Science ®Google Scholar
• Boyd AS, Neldner KH. Hydroxyurea therapy. J Am Acad Dermatol 1991; 25: 518–524
   PubMed Web of Science ®Google Scholar
• Renfro L, Kamino H, Raphael B, Moy J, Sanchez M. Ulcerative lichen planus-like dermatitisassociated with hydroxyurea. J Am Acad Dermatol 1991; 24: 143–145
   PubMed Web of Science ®Google Scholar
• Daoud MS, Gibson LE, Pittelkow MR. Hydroxyurea dermatopathy : A unique lichenoid eruption complicating long term therapy with hydroxyurea. J Am Acad Dermatol 1997; 36: 178–182
   PubMed Web of Science ®Google Scholar
• Mertez LE, Conn DL. Vasculitis associated with malignancy. Current Opinion in Rheumatol. 1992; 4: 39–46
   PubMedGoogle Scholar
• Greer JM, Longley S, Edwards NL, Elfenbein GJ, Panush RS. Vasculitis associated with malignancy : experience with 13 patients and literature review. Medicine 1988; 67: 222–230
   Google Scholar
• Motefusco E, Alimena G, Gastaldi R, Carlesimo OA, Valesini G, Mandelli F. Unusual dermatologic toxicity of long-term therapy with hydroxyurea in chronic myelogenous leukemia. Tumori 1986; 72: 317–321
   PubMed Web of Science ®Google Scholar
• Nguyen TV, Margolis DJ. Hydroxyurea and lower leg ulcers. Cutis 1993; 52: 217–219, 1993.
   PubMed Web of Science ®Google Scholar
• Cox C, Nowicky D, Young R. Hydroxyurea-related ankle ulcers in patients with myeloproliferative disorders : A case report and review of the literature. Annals of Plastic Surgery 1997; 39: 546–549
   PubMed Web of Science ®Google Scholar
• Best PJ, Daoud MS, Pittelkow MR, Pettit RM. Hydroxyurea-induced leg ulceration in 14patients. Annals of Int Med 1998; 128: 29–32
   PubMed Web of Science ®Google Scholar
• Yarbro JW, Kennedy BJ, Barnum CP. Hydroxyurea inhibition of DNA synthesis in ascites tumor. Proc Natl Acad Sci USA 1965; 53: 1033–1035
   PubMed Web of Science ®Google Scholar
• Thelander L, Reichard P. Reduction of nbonucle-otides. Annu Rev Biochem 1979; 48: 133–158
   PubMed Web of Science ®Google Scholar
• Plucinski TM, Fager RS, Reddy GPV. Allosteric interaction of components of the reptilase complex is responsible for enzyme cross inhibition. Mol Pharmacol 1990; 38: 114–120
   PubMed Web of Science ®Google Scholar
• Farber E, Baserga R. Differential effects of hydroxyurea on survival of proliferating cells in vivo. Cancer Res 1969; 29: 136–139
   PubMed Web of Science ®Google Scholar
• Smith C, Gelfant S. Effects of rnethotrexate and hydroxyurea on psoriatic epidermis. Arch Dennatol 1974; 110: 70–72
   PubMed Web of Science ®Google Scholar
• Yarbro JW. Mechanism of action of hydroxyurea. Seminars in Oncol. 1992; 19(suppl. 9)1–10
   PubMedGoogle Scholar
• Woofter JC, Anderson PC. Megaloblastic anemia in the management of severe psoriasis. W V Med J 1975; 71: 352–353
   PubMedGoogle Scholar
• Al-Momen AK. Recombinant human erythropoeitin induced rapid healing of a chronic leg ulcer in a patient with sickle cell disease. Acta Haematol 1975; 86: 46–48
   Google Scholar
• Charache S, Dover GJ, Moore RD, Eckert S, Ballas SK, Koshy M, Milner PF, Orringer EP, Phillips G, Jr, Plan OS, et al. Hydroxyurea : Effects on hemoglobin F production in patients with sickle cell anemia. Blood 1992; 79: 2555–2565
   PubMed Web of Science ®Google Scholar
• Charache S, Tenin ML, Moore RD, Dover GJ, Barton FB, Eckert SV, McMahon Rp, Bonds DR. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the multicenter study of hydroxyurea in sickle cell anemia. N Eng J Med. 1995; 332: 1317
   Google Scholar